



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/541,044

05/08/2006

Benjamin L Miller

176/61442

1984

7590

10/28/2008

Nixon Peabody
Clinton Square
PO Box 31051
Rochester, NY 14603-1051

EXAMINER

BAUSCH, SARAE L

ART UNIT

PAPER NUMBER

1634

MAIL DATE

DELIVERY MODE

10/28/2008

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 10/541,044	Applicant(s) MILLER ET AL.	
	Examiner SARAE BAUSCH	Art Unit 1634	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 28 July 2008.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-66 is/are pending in the application.
- 4a) Of the above claim(s) 29-36 and 44-66 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-28 and 37-43 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 24 June 2005 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date <u>04/07, 11/06, 06/05</u> . | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

1. This action is in response to applicants correspondence mailed 07/28/2008.

Election/Restrictions

2. Applicant's election with traverse of group I, claims 1-28 and 37-43 and SEQ ID NO 1 in the reply filed on 07/28/2008 is acknowledged. The traversal is on the ground(s) that the groups are closely related and can be searched without undue burden. This is not found persuasive because this application is a national stage application under 35 USC 371 and as such is required under rule 13.1 that the application be related to one invention only or a group of inventions linked to form a single general inventive concept and the special technical feature define a contribution when considered as a whole over the prior art, as defined in Rule 13.2. Burden is not a criteria that is used for unity of inventions in a national stage application under 35 USC 371. As such, as stated in the restriction requirement mailed 01/28/2008, the special technical feature is a nucleic acid probe comprising a first end being modified for coupling to a surface and a second end being bound to a fluorophore. This special technical feature is not a contribution over the prior art as Dubertert et al. teaches molecular beacons that comprise a nucleic acid that is coupled to a gold nanoparticle. Thus the technical feature that links the groups does not constitute a special technical feature over the prior art.

The requirement is still deemed proper and is therefore made FINAL.

3. Claims 29-36 and 44-66 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking

Art Unit: 1634

claim. Applicant timely traversed the restriction (election) requirement in the reply filed on 07/28/2008.

Drawings

4. The drawings are acceptable.

Claim Rejections - 35 USC § 102

5. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

6. Claims 1-3, 5-6, 9-10, 14-15, 17-24, 37, 39, 41-42 are rejected under 35 U.S.C. 102(b) as being anticipated by Dubertret et al. (2001, cited on IDS submitted 04/07).

With regard to claim 1, 14-15, 37, 39 and 41, Dubertret et al. teaches covalent linkage of a gold nanoparticle (fluorescence quenching surface) by modified primary amine at the 3' end of the nucleic acid and a disulfide at the 5' end (claim 15 and 41) (1st end being modified for coupling to a surface) to a 25 base sequence that adopts a hairpin loop structure. Dubertret et al. teaches the molecule comprises at the 5' end of DNA (claim 14, claim 39) is attached a gold particle followed by a 25 base sequence that has five nucleotides that are complementary and a fluorophore attached to the 3' end (see pg. 365, 2nd column, 2nd full paragraph and figure 1).

With regard to claims 2-3 and 5-6, Dubertret teaches the nucleic acid is attached to gold particle (substrate, claim 2) (conductive metal, gold, claims 5-6) and teaches the nucleic acid is

Art Unit: 1634

attached to the entire particle (present over substantially all the substrate) (claim 3) (see figure 1B).

With regard to claim 9-10 and 42, Dubertret teaches the fluorophore that is attached to DNA is fluorescein, rhodamine, texas red or Cy5 (see table 1).

With regard to claim 17, Dubertret et al. teaches five nucleotides are complementary to form a hairpin loop structure (see pg. 365, 2nd column, 2nd full para).

With regard to claim 18-20 and 24, Dubertret et al. teaches four different fluorophores attached to a DNA-gold conjugate (see table 1) therefore Dubertret et al. teaches a second nucleic acid (additional nucleic acid) that is different from the first nucleic acid, because each of the fluorophores that are conjugated to the nucleic acid are different (claim 20). Since Dubertret et al. teaches different molecules Dubertret et al. teaches each of the nucleic acid molecules are bound to the quenching surface (gold particles) at discrete locations, as each nucleic acid is bound to a different particle, which is a discrete location (claim 19).

With regard to claim 21-23, Dubertret et al. teaches four different fluorophores attached to probe-gold conjugated particles (claim 22) (see table 1). Dubertret et al. teaches for each gold-probe-dye conjugate the nucleic acid is attached at a single location on the particle (see figure 1B) thus Dubertret et al teach both a first and second nucleic acid molecule bound to a single location (a single particle). Each of the fluorophores attached to the probe-gold conjugate have different fluorescence emission spectra that is separated by at least 1nm (see 1st column, 1st full para).

7. Claims 1-11, 14-21, 24, 26-28, 37-42 are rejected under 35 U.S.C. 102(b) as being anticipated by Cass et al. (US Patent 6312906, cited on IDS).

Art Unit: 1634

With regard to claim 1 and 37, Cass et al. teach a device that comprises a solid phase surface comprising a material that quenches fluorescence (fluorescence quenching surface), a self complementary single stranded oligonucleotide probe linked to the solid surface and the probe comprising a fluorophore attached to the other end (see column 3 lines 42-50 and claim 27). Cass et al. teach modification of the oligonucleotide probe to attach to the solid surface (see column 10 lines 10-50)

With regard to claim 2-4, Cass et al. teach the fluorescence surface quenching area of the sheet or in pattern such as dots or lines (substantially entire substrate and plurality of discrete locations) (see columns 9 lines 34-50 and column 13 lines 6-15).

With regard to claims 5-8, Cass et al. teach solid surface that comprise gold, silver, and quartz doped with transition metal (see column 9 lines 10-20). Cass teaches that solid phases can be semiconductors such as N type or P type doped material (See column 15 lines 30-40 and claim 18).

With regard to claim 9-11 and 42, Cass et al. teach fluorophores that are rhodamine dyes as well as phycobilliproteins (see column 8, lines 32-48).

With regard to claim 14-16 and 38-40, Cass et al. teach the nucleic acid can be RNA, DNA or PNA (see figure 4 and column 6 lines 60-65).

With regard to claim 17, Cass et al. teach at least 6-12 contiguous nucleotides complementary to the nucleic acid (see column 6 lines 45-50 and column 17 lines 1-5).

With regard to claims 18-21 and 24, Cass et al. teach individual species of probes (one or more additional nucleic acids that are different) are immobilized on solid support that has a set of

Art Unit: 1634

discrete and isolated regions on a substrate (bound to first and second discrete locations) (See column 13 lines 25-67).

With regard to claims 26-28, Cass et al. teach variable length spacers attached to the end of oligonucleotides. Additionally, Cass et al. teach mixing long chain amino alcohols to intersperse DNA which results in attachment of oligonucleotides down to 50nm apart on the surface (see column 10, lines 20-38).

With regard to claims 41, Cass et al. teach thiol modified oligonucleotides (thiol modified base) (see column 10 lines 38-48).

Claim Rejections - 35 USC § 103

8. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

9. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Art Unit: 1634

10. Claims 12-13 and 22-23 are rejected under 35 U.S.C. 103(a) as being unpatentable over Cass et al. (US Patent 6312906, cited on IDS) in view of Bruchez et al. (US 2002/0034747).

Cass et al. teach a device that comprises a solid phase surface comprising a material that quenches fluorescence (fluorescence quenching surface), a self complementary single stranded oligonucleotide probe linked to the solid surface and the probe comprising a fluorophore attached to the other end (see column 3 lines 42-50 and claim 27). Cass et al. teach modification of the oligonucleotide probe to attach to the solid surface (see column 10 lines 10-50). Cass does not teach semiconductor nanocrystals attached to the nucleic acid probe nor does Cass teach that two different fluorophores that are different.

Bruchez et al. teaches the use of semiconductor nanocrystal labels attached to different polynucleotides to allow for simultaneous analysis of multiple polynucleotides (see para 16 and para 42-43). Bruchez et al. teaches a semiconductor nanocrystal attached to a probe which can be a molecular beacon (see para 13 and figure 1A). Bruchez et al. teaches a semiconductor nanocrystal comprises a core and shell that is a semiconductor material (See para 59 and 61) (claims 12-13). Bruchez et al. teaches using more than one semiconductor nanocrystal that has at least one different fluorescence characteristic, including emission spectra (see para 83).

Therefore, it would have been prima facie obvious to one of ordinary skill in the art at the time the invention was made to improve the nucleic acid probe attached to a quenching surface and fluorophore by Cass et al. to include different fluorophores, including different semiconductor nanocrystal fluorophores, as taught by Bruchez, to improve the nucleic acid probe of Cass and allow for more versatility in fluorescence. The ordinary artisan would have been motivated to improve the type of fluorophore attached to the nucleic acid of Cass et al. to include

Art Unit: 1634

the semiconductor nanocrystal of Bruchez because Bruchez teaches that the nanocrystals allow for multiplexing of detection of different nucleic acids, using different emission wavelengths, and allows for higher assay throughput, decreased cross contamination resulting in more reliable results as well real time monitoring (see para 17). The ordinary artisan would have had a reasonable expectation of success that the use of semiconductor nanocrystals could be used as fluorophores in the nucleic acid probes taught by Cass et al. because both Cass et al. and Bruchez et al. teach molecular beacon probes that form hairpin structures with a fluorophore on one end of the probe and a quencher on the other end. Additionally, because both Cass et al. and Bruchez et al. teach molecular beacon probes with fluorophores and quenchers attached to the nucleic acid probe, it would have been obvious to one skilled in the art to substitute known elements, semiconductor nanocrystals as taught by Bruchez for the fluorescent dye as taught by Cass in order to achieve the predictable result of higher assay throughput.

11. Claims 25 and 43 are rejected under 35 U.S.C. 103(a) as being unpatentable over Cass et al. (US Patent 6312906, cited on IDS) in view of Vannuffel et al. (J. Clin. Microbiology, 1995, vol. 33, pp. 2864-2867), Berger-Bachi et al. (GenBank accession No. X17688, gi 46579) and Hogan et al. (US Pat. 5,541,308, July 30, 1996).

Cass et al. teach a device that comprises a solid phase surface comprising a material that quenches fluorescence (fluorescence quenching surface), a self complementary single stranded oligonucleotide probe linked to the solid surface and the probe comprising a fluorophore attached to the other end (see column 3 lines 42-50 and claim 27). Cass et al. teach modification of the oligonucleotide probe to attach to the solid surface (see column 10 lines 10-50). Cass et al. teaches complementary region within the nucleic acid probe of at least 6 to 10 nucleotides

Art Unit: 1634

(see column 6 lines 45-50 and column 17 lines 1-5). Cass teaches that the target region of the probe is preferably from 15 to 60 nucleotides in length and more preferably from about 18 to about 40 nucleotides in length (see column 6 lines 50-55). Cass does not teach SEQ ID NO: 1.

Vannuffel teach detection of methicillin resistant staphylococcus by multiplex PCR by detection of the FemA gene (see abstract). Vannuffel teaches four different oligonucleotide probes that detect and are complementary to the FemA gene (see oligonucleotides, pg. 2865) as taught by Berger-Bachi et al. Vannuffel teaches that multiplex PCR for the FemA gene allows for rapid and specific identification of resistance patterns and pathogens (see pg. 2867, last para). Vannuffell teaches detection of femA has a high level sensitivity 100% and teaches that FemA is unique to *S. aureus* which allows for specific detection (see pg. 2867, 1st para). Thus, Vannuffell teaches that detection of FemA gene allows for specific species identification of *S. aureus* with high sensitivity.

Berger-Bachi et al. teaches the entire sequence of the FemA gene, GenBank accession number X17688, which comprises nucleotides 700 to 731 which are identical to nucleotides 10-41 of SEQ ID NO: 1.

Additionally, Hogan et al. (herein referred to as Hogan) teaches the use of specific probes col. 6-7, lines 50-67, lines 1-12, and furthermore provides specific guidance for the selection of probes,

"Once the variable regions are identified, the sequences are aligned to reveal areas of maximum homology or 'match'. At this point, the sequences are examined to identify potential probe regions. Two important objectives in designing a probe are to maximize homology to the target sequence(s) (greater than 90% homology is recommended) and to minimize homology to non-target sequence(s) (less than 90% homology to non-targets is recommended). We have identified the following useful guidelines for designing probes with the desired characteristics.

Art Unit: 1634

First, probes should be positioned so as to minimize the stability of the probe:nontarget nucleic acid hybrid. This may be accomplished by minimizing the length of perfect complementarity to non-target organisms, avoiding G and C rich regions of homology to non-target sequences, and by positioning the probe to span as many destabilizing mismatches as possible (for example, dG:rU base pairs are less destabilizing than some others). Second, the stability of the probe:target nucleic acid hybrid should be maximized. This may be accomplished by avoiding long A and T rich sequences, by terminating the hybrids with G:C base pairs and by designing the probe with an appropriate T_m . The beginning and end points of the probe should be chosen so that the length and %G and %C result in a T_m about 2-10°C higher than the temperature at which the final assay will be performed. The importance and effect of various assay conditions will be explained further herein. Third, regions of the rRNA which are known to form strong structures inhibitory to hybridization are less preferred. Finally, probes with extensive self complementarity should be avoided."

Hogan teaches that "while oligonucleotide probes of different lengths and base composition may be used, oligonucleotide probes preferred in this invention are between about 15 and about 50 bases in length" (col. 10, lines 13-15). Oligonucleotides complementary to sequences adjacent to the probe regions were synthesized and used in the hybridization mix according to Hogan et al., U.S. Pat. No. 5,030,557, filed Nov. 24, 1987, entitled "Means and Method for Enhancing Nucleic Acid Hybridization (the "helper " patent application). Hogan teaches that oligonucleotide probes may be labeled by any of several well known methods such as radioisotopes, non-radioactive reporting groups, non-isotopic materials such as fluorescent molecules (col. 10, lines 45-60). Hogan teaches that probes may be labeled using a variety of labels, as described within, and may be incorporated into diagnostic kits.

Therefore, it would have been prima facie obvious to one of ordinary skill in the art at the time the invention was made to improve the nucleic acid probes taught by Cass et al. to include a probe to detect FemA gene as taught by Vannuffel and the sequence taught by Berger-Bachi et al. to allow for detection of *S. aureus*. The ordinary artisan would have been motivated to improve the nucleic acid probes taught by Cass et al. with a probe target sequence specific for

Art Unit: 1634

FemA as taught by Vannuffel and Berger-Bachi because Vannuffel teaches detection of FemA gene allows for a sensitive and specific assay for methicillin resistant *S. aureus*. The ordinary artisan would have had a reasonable expectation of success that the use of hairpin loop, including a stem loop structure and target region, as taught by Cass et al. to include a sequence that is specific for FemA because both Vannuffell and Berger-Bachi teach the sequence of the FemA and specificity of detecting FemA gene and Cass et al. teaches that nucleic acid probes allow for simultaneous detection of multiple nucleic acid species from the same sample.

Additionally, designing probes which are equivalents to those taught in the art is routine experimentation. The prior art teaches the parameters and objectives involved in the selection of oligonucleotides that function as probes and primers, see Hogan et al. and Cass et al. Moreover there are many internet web sites that provide free downloadable software to aid in the selection of probes drawn from genetic data recorded in a spreadsheet. The prior art is replete with guidance and information necessary to permit the ordinary artisan in the field of nucleic acid detection to design probes. As discussed above, the ordinary artisan would be motivated to have designed and test new molecular beacon probes to obtain additional oligonucleotides that function to detect FemA gene and identify oligonucleotides with improved properties. The ordinary artisan would have a reasonable expectation of success of obtaining additional probes from within the alignment provided by Berger-Bach, including a stem loop of 6 to 10 complementary nucleotides to allow for the detection of the FemA gene using molecular beacon probes features taught by Cass. Thus, for the reasons provided above, the ordinary artisan would have designed additional probes, including a probe with the SEQ ID NO 1 using the teachings in the art at the time the invention was made.

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

12. Claims 1-28 and 37-43 provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-14 of copending Application No. 11/838616. Although the conflicting claims are not identical, they are not patentably distinct from each other because instant claim 1 is generic to all that is recited in claim 7 of '616 and instant claim 37 is generic to all that is recited in claim 1 of '616. Claims 2-6 and 8-14 of '616 fall entirely in the scope of instant claims 2-28 and 38-43.

Specifically the sensor chip comprising a quenching surface and a first nucleic acid that hybridizes to *Staphylococcus*, a first fluorophore tethered to the first end of the nucleic acid of '616 anticipates the genus of a sensor chip comprising a quenching surface, a first nucleic acid that has a first fluorophore attached to the first end and a second region that is able to hybridize to the first region in the instant application. Furthermore, fluorescence quenching surfaces, fluorophores, and semiconductor metals of the instant application is disclosed in '616

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

13. Claims 1-28 and 37-43 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 18-26 of copending Application No. 10/584875. Although the conflicting claims are not identical, they are not patentably distinct from each other because instant claim 1 is generic to all that is recited in claim 18 of '875. Claims 19-26 of '875 fall entirely in the scope of instant claims 2-28 and 38-43.

Specifically the isolated nucleic acid comprising a fluorescent label tethered to one terminus of the nucleic acid molecule comprising a hairpin and a quenching agent tethered to the other terminus of '875 anticipates a sensor chip comprising a fluorescence quenching surface and a first nucleic acid molecule with a first region complementary to a second region wherein the first end bound to the quenching surface and the second end bound to a fluorophore of instant claim 1. Additionally quenching surfaces, quenching agents that are metal, fluorescent label that are dyes of the instant application are disclosed in '875 (specifically claims 22-26).

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

14. Claims 1-28 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-8, 11, 13-14, 17-21 of U.S. Patent No. 7442510 (US Patent Application 11/553904). Although the conflicting claims are not identical, they are not patentably distinct from each other because instant claim 1 is generic to all that is recited in

Art Unit: 1634

claim 1 of '510. Claims 2-8, 13-14, 17-21 of '510 fall entirely in the scope of instant claims 2-28.

Specifically the isolated nucleic acid comprising a hairpin DNA molecule that hybridizes over its full length to a target nucleic acid that has a naturally occurring sequence, label tethered to one terminus of the hairpin molecule and a quenching agent tethered to the other terminus of '510 anticipates a sensor chip comprising a fluorescence quenching surface and a first nucleic acid molecule with a first region complementary to a second region wherein the first end bound to the quenching surface and the second end bound to a fluorophore of instant claim 1.

Additionally, SEQ ID NO. 1 of instant claim 25 is a sequence of FemA gene from *S. Aureus*, which is a naturally occurring sequence. Furthermore solid surfaces, quenching agents that are metal, fluorescent label that are dyes of the instant application are disclosed in '510 (specifically claims 2-8).

15. Claims 37-43 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-8, 11, 13-14, 17-21 of U.S. Patent No. 7442510 (US Patent application 11/553904) in view of Cass et al. (US Patent 6312906). Although the conflicting claims are not identical, they are not patentably distinct from each other because claim 1 of '510 is drawn to an isolated nucleic acid probe comprising a hairpin, a label tethered to one terminus and a quenching agent tethered to the other terminus while instant claim 37 comprises a nucleic acid probes comprising a first end being modified for coupling to a surface and second end being bound to a fluorophore. Claim 1 of '510 does not recite a first end being modified for coupling to a surface, however Cass et al. teaches attachment of a quenching surface to a nucleic acid molecule via a modified end of a nucleic acid (see column 10 lines 38-

Art Unit: 1634

48). Therefore, the modified end of the instantly claimed invention encompasses the nucleic acid probe of '510. Additionally, SEQ ID NO. 1 of instant claim 43 is a sequence of FemA gene from S. Aureus, which is a naturally occurring sequence. Furthermore fluorescent label that are dyes of the instant application are disclosed in '510 (specifically claims 2-8).

Conclusion

16. No claims are allowable.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sarae Bausch whose telephone number is (571) 272-2912. The examiner can normally be reached on M-F 9am-5pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ram Shukla can be reached on (571) 272-0735. The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at (866) 217-9197 (toll-free).

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Art Unit: 1634

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

/Sarae Bausch/

Primary Examiner, Art Unit 1634

/Ram R. Shukla/

Supervisory Patent Examiner, Art Unit 1634

/George C. Elliott, Ph.D./

Director, Technology Center 1600